Related Experiment Videos
The natural history of minicore-multicore myopathy
1Department of Neuropathology, Royal Perth Hospital, Western Australia.
Abstract:
To determine the natural history of minicore-multicore myopathy (MMM) we studied 5 patients who were found to have this disorder from 6 to 16 years ago. Four of these patients had improved muscle strength since their original assessment and one patient had deteriorated. There were no clinical electrophysiological or pathological features that distinguished this last patient from the others. We conclude, therefore, that most patients with MMM may be expected to improve as time passes but, for unknown reasons, a minority may deteriorate. This information should be helpful to clinicians in their prognostic advice to new patients.
Insights
Most patients with minicore-multicore myopathy (MMM) show improved muscle strength over time. However, a small number may unexpectedly deteriorate, highlighting the unpredictable nature of this rare neuromuscular disorder.
Area of Science:
- Neurology
- Muscle Diseases
Background:
- Minicore-multicore myopathy (MMM) is a rare neuromuscular disorder.
- Understanding the long-term prognosis of MMM is crucial for patient care.
Purpose of the Study:
- To investigate the natural history and long-term progression of minicore-multicore myopathy.
- To identify factors influencing disease course in MMM patients.
Main Methods:
- Longitudinal study of 5 patients diagnosed with MMM 6-16 years prior.
- Assessment of clinical, electrophysiological, and pathological features.
- Tracking changes in muscle strength over time.
Main Results:
- Four out of five patients demonstrated improved muscle strength.
- One patient experienced disease deterioration.
- No distinct clinical, electrophysiological, or pathological markers differentiated the patient who deteriorated.
Conclusions:
- Most individuals with minicore-multicore myopathy can anticipate improvement.
- A subset of patients may experience unexplained deterioration.
- Findings aid clinicians in providing prognostic guidance for MMM.